Safety considerations for withdrawal of nucleos(t)ide analogues in patients with chronic hepatitis B: First, do no harm

Nucleos(t)ide analogues (NA) are widely used to treat hepatitis B virus (HBV) infection, but they cannot eradicate the virus and treatment duration can be lifelong if the endpoint is set at seroclearance of the hepatitis B surface antigen (HBsAg). As an alternative strategy, finite NA therapy withou...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Yao-Chun, Tseng, Cheng-Hao, Kao, Jia-Horng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association for the Study of the Liver 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10577354/
https://www.ncbi.nlm.nih.gov/pubmed/36916171
http://dx.doi.org/10.3350/cmh.2022.0420

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10577354/
https://www.ncbi.nlm.nih.gov/pubmed/36916171
http://dx.doi.org/10.3350/cmh.2022.0420

Ejemplares similares